Preclinical assessment of thrombin-preconditioned human Wharton's jelly-derived mesenchymal stem cells for neonatal hypoxic-ischaemic brain injury
This study was conducted to evaluate the tissue distribution and potential toxicity of thrombin-preconditioned human Wharton's jelly-derived mesenchymal stem cells (th-hWJMSCs) in animal models before the initiation of clinical trials. We investigated the biodistribution, tumorigenicity and general toxicity of th-hWJMSCs. MSCs were administered the maximum feasible dose (1 × 105 cells/10 µL/head) once, or at lower doses into the cerebral ventricle. To support the clinical use of th-hWJMSCs for treating brain injury, preclinical safety studies were conducted in newborn Sprague-Dawley rats and BALB/c nude mice. In addition, growth parameters were evaluated to assess the impact of th-hWJMSCs on the growth of newborn babies. Our results suggest that th-hWJMSCs are non-toxic and non-tumorigenic in rodent models, survive for up to 7 days in the brain and hold potential for HIE therapy.PMID:34651412 | DOI:10.1111/jcmm.16971
Source: J Cell Mol Med - Category: Molecular Biology Authors: Jung-Ho Noh Ji-Seong Jeong Sang-Jin Park Kyung Jin Jung Byoung-Seok Lee Woo-Jin Kim Ji-Seok Han Min-Kyung Cho Dong Kyung Sung So Yoon Ahn Yun Sil Chang Hwa-Young Son Eun Ju Jeong Source Type: research
More News: Babies | Brain | Clinical Trials | Hypothermia | Molecular Biology | Neurology | Perinatology & Neonatology | Stem Cell Therapy | Stem Cells | Study | Toxicology